A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Retained Products of Conception, Miscarriage, Conservative Management. Basic parameters: No limits · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV). The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment？ Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.
Primary outcome measures
- The disappearance rate of RPOC [Time frame: After conservative treatment, transvaginal ultrasound was performed at the end of the second menstrual cycle (calculated from the first day of menses, 28-30 days per cycle) to assess RPOC resolution]
Secondary outcome measures (1)
- the disappearance rate of EMV [Time frame: Immediately after the completion of conservative treatment]
Eligibility criteria
Inclusion criteria
- Recent history of miscarriage or delivery (within the past 8 weeks)
- Strong willingness to undergo conservative management
- Hemodynamically stable
- Signed informed consent form
Exclusion criteria
- Heavy vaginal bleeding (requiring immediate surgical intervention)
- Active pelvic or systemic infection (e.g., fever >38°C, elevated CRP/WBC)
- Severe dysfunction of vital organs (heart, liver, or kidney)
- Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)
- Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels)
- Placenta accreta spectrum disorders diagnosed during current pregnancy
- History of uterine artery embolization
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Hysteroscopy Center, Fuxing Hospital, Capital Medical University — Beijing
Identifiers
NCT: NCT06862089 · 2024FXHEC-KSP073